MC1R Gene Variants and Non-melanoma Skin Cancer: a Pooled-analysis from the M-SKIP Project

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Jun 24

PMID 26103569

Citations 32

Authors

E Tagliabue

M C Fargnoli

S Gandini

P Maisonneuve

F Liu

M Kayser

T Nijsten

J Han

R Kumar

N A Gruis

L Ferrucci

W Branicki

T Dwyer

L Blizzard

P Helsing

P Autier

J C Garcia-Borron

P A Kanetsky

M T Landi

J Little

J Newton-Bishop

F Sera

S Raimondi

Affiliations

Soon will be listed here.

Abstract

Background: The melanocortin-1-receptor (MC1R) gene regulates human pigmentation and is highly polymorphic in populations of European origins. The aims of this study were to evaluate the association between MC1R variants and the risk of non-melanoma skin cancer (NMSC), and to investigate whether risk estimates differed by phenotypic characteristics.

Methods: Data on 3527 NMSC cases and 9391 controls were gathered through the M-SKIP Project, an international pooled-analysis on MC1R, skin cancer and phenotypic characteristics. We calculated summary odds ratios (SOR) with random-effect models, and performed stratified analyses.

Results: Subjects carrying at least one MC1R variant had an increased risk of NMSC overall, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC): SOR (95%CI) were 1.48 (1.24-1.76), 1.39 (1.15-1.69) and 1.61 (1.35-1.91), respectively. All of the investigated variants showed positive associations with NMSC, with consistent significant results obtained for V60L, D84E, V92M, R151C, R160W, R163Q and D294H: SOR (95%CI) ranged from 1.42 (1.19-1.70) for V60L to 2.66 (1.06-6.65) for D84E variant. In stratified analysis, there was no consistent pattern of association between MC1R and NMSC by skin type, but we consistently observed higher SORs for subjects without red hair.

Conclusions: Our pooled-analysis highlighted a role of MC1R variants in NMSC development and suggested an effect modification by red hair colour phenotype.

Citing Articles

Changes in Skin Cancer-Related Behaviors, Distress, and Beliefs in Response to Receipt of Low- to Moderate-Penetrance Genetic Test Results for Skin Cancer Risk.

Khadka M, Lacson J, Sutton S, Kim Y, Vadaparampil S, Soto-Torres B Cancers (Basel). 2024; 16(23).

PMID: 39682213 PMC: 11640494. DOI: 10.3390/cancers16234027.

The Risk Information and Skin-cancer Education for Undergraduate Prevention (RISE-UP) Study: Protocol for a Trial of Personalized Sun Protection Interventions for Skin Cancer Prevention among Undergraduate Students.

Wu Y, Woodside L, Kaphingst K, Jensen J, Hamilton J, Kohlmann W Contemp Clin Trials. 2024; 147:107728.

PMID: 39491719 PMC: 11620905. DOI: 10.1016/j.cct.2024.107728.

Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.

Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L JCO Precis Oncol. 2024; 8:e2300702.

PMID: 38662983 PMC: 11513442. DOI: 10.1200/PO.23.00702.

Personalized treatment concepts in extraocular cancer.

Ju S, Rokohl A, Guo Y, Yao K, Fan W, Heindl L Adv Ophthalmol Pract Res. 2024; 4(2):69-77.

PMID: 38590555 PMC: 10999489. DOI: 10.1016/j.aopr.2024.02.003.

Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma.

Wunderlich K, Suppa M, Gandini S, Lipski J, White J, Del Marmol V Cancers (Basel). 2024; 16(5).

PMID: 38473375 PMC: 10931186. DOI: 10.3390/cancers16051016.

References

Lomas A, Leonardi-Bee J, Bath-Hextall F . A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166(5):1069-80. DOI: 10.1111/j.1365-2133.2012.10830.x. View

Smith R, Healy E, Siddiqui S, Flanagan N, Steijlen P, Rosdahl I . Melanocortin 1 receptor variants in an Irish population. J Invest Dermatol. 1998; 111(1):119-22. DOI: 10.1046/j.1523-1747.1998.00252.x. View

Harland M, Goldstein A, Kukalizch K, Taylor C, Hogg D, Puig S . A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer. 2008; 44(9):1269-74. PMC: 2494985. DOI: 10.1016/j.ejca.2008.03.005. View

April C, Barsh G . Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation. PLoS Genet. 2007; 3(1):e9. PMC: 1774588. DOI: 10.1371/journal.pgen.0030009. View

Brudnik U, Branicki W, Wojas-Pelc A, Kanas P . The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. Exp Dermatol. 2008; 18(2):167-74. DOI: 10.1111/j.1600-0625.2008.00760.x. View

Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R . Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer. 2007; 121(9):2105-2108. DOI: 10.1002/ijc.22952. View

Slominski A, Paus R, Wortsman J . Can some melanotropins modulate keratinocyte proliferation?. J Invest Dermatol. 1991; 97(4):747. DOI: 10.1111/1523-1747.ep12484829. View

Levi F, Te V, Randimbison L, Erler G, La Vecchia C . Trends in skin cancer incidence in Vaud: an update, 1976-1998. Eur J Cancer Prev. 2001; 10(4):371-3. DOI: 10.1097/00008469-200108000-00011. View

Pasquali E, Garcia-Borron J, Fargnoli M, Gandini S, Maisonneuve P, Bagnardi V . MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project. Int J Cancer. 2014; 136(3):618-31. PMC: 4378685. DOI: 10.1002/ijc.29018. View

10.

Sanchez-Laorden B, Jimenez-Cervantes C, Garcia-Borron J . Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer. J Biol Chem. 2006; 282(5):3241-51. DOI: 10.1074/jbc.M606865200. View

11.

Flohil S, de Vries E, Neumann H, Coebergh J, Nijsten T . Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol. 2011; 91(1):24-30. DOI: 10.2340/00015555-1009. View

12.

Sanchez-Laorden B, Herraiz C, Valencia J, Hearing V, Jimenez-Cervantes C, Garcia-Borron J . Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: Steady-state retention of mutant forms in the proximal golgi. J Cell Physiol. 2009; 220(3):640-54. PMC: 2705480. DOI: 10.1002/jcp.21804. View

13.

Duffy D, Box N, Chen W, Palmer J, Montgomery G, James M . Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet. 2004; 13(4):447-61. DOI: 10.1093/hmg/ddh043. View

14.

Dwyer T, Stankovich J, Blizzard L, FitzGerald L, Dickinson J, Reilly A . Does the addition of information on genotype improve prediction of the risk of melanoma and nonmelanoma skin cancer beyond that obtained from skin phenotype?. Am J Epidemiol. 2004; 159(9):826-33. DOI: 10.1093/aje/kwh120. View

15.

Jones F, Ramachandran S, Lear J, Smith A, Bowers B, Ollier W . The melanocyte stimulating hormone receptor polymorphism: association of the V92M and A294H alleles with basal cell carcinoma. Clin Chim Acta. 1999; 282(1-2):125-34. DOI: 10.1016/s0009-8981(99)00017-0. View

16.

Bohm M, Wolff I, Scholzen T, Robinson S, Healy E, Luger T . alpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem. 2004; 280(7):5795-802. DOI: 10.1074/jbc.M406334200. View

17.

Gerstenblith M, Goldstein A, Fargnoli M, Peris K, Landi M . Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat. 2007; 28(5):495-505. DOI: 10.1002/humu.20476. View

18.

Wikberg J, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C . New aspects on the melanocortins and their receptors. Pharmacol Res. 2000; 42(5):393-420. DOI: 10.1006/phrs.2000.0725. View

19.

Box N, Wyeth J, OGorman L, Martin N, Sturm R . Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet. 1997; 6(11):1891-7. DOI: 10.1093/hmg/6.11.1891. View

20.

Luisa Kadekaro A, Leachman S, Kavanagh R, Swope V, Cassidy P, Supp D . Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J. 2010; 24(10):3850-60. PMC: 3229421. DOI: 10.1096/fj.10-158485. View